.jpg "Panagiotis Bakouros, MSc photo")
Biologist
Flow Cytometry Unit, Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece, Greece
Mr. Panagiotis Bakouros, MSc, is a PhD candidate at the Flow Cytometry Unit of the Department of Biology at the National and Kapodistrian University of Athens (NKUA). graduated from the Department of Biology at the University of Patras (2016-2020). His undergraduate thesis focused on the effect of p-coumaric acid on the survival and phagocytosis of human neutrophils, under the supervision of Assistant Professor, Dr. Eleftheria Rosmaraki.
In 2022, Mr. Bakouros graduated from the postgraduate program of the Department of Biology and the Medical School of NKUA, titled "Applications of Biology in Medicine." For his master's thesis, he studied the immune response after SARS-CoV-2 vaccination using flow and mass cytometry techniques under the supervision of Postdoctoral Researcher Dr. Nikolaos Paschalidis at BRFAA and Professor of Immunology Dr. Ourania Tsitsilonis at NKUA.
Since 2023, Mr. Bakouros has been a PhD candidate in the Flow Cytometry Unit of the Department of Biology at NKUA, under the supervision of Professor Dr. Ourania Tsitsilonis. His dissertation, titled "Identification of New Prognostic and Predictive Biomarkers in Multiple Myeloma," focuses on studying the bone marrow microenvironment to identify cellular subpopulations that can serve as biomarkers for the progression of Multiple Myeloma (MM) from its asymptomatic stages (MGUS, sMM) to symptomatic MM. Concurrently, he is also involved in studying cellular senescence in Multiple Myeloma using flow cytometry with a new fluorescent analog, GLF-16.
His doctoral dissertation is part of the research conducted by the Flow Cytometry Unit of the Department of Biology at NKUA, within the framework of the European Program ELMUMY.
Mr. Panagiotis Bakouros has participated in oral presentations at the 49th and 50th Annual Panhellenic Medical Conferences, and in a scientific publication in the American Journal of Hematology titled "Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma."